FDA patent list reforms are now firmly on the US legislative agenda
Unanimous votes by the House of Representatives signal that changes to the Orange and Purple Books stand a good chance of being implemented
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.